Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 5

Montelukast: its role in the treatment of childhood asthma

Authors Koray Harmanci

Published 15 November 2007 Volume 2007:3(5) Pages 885—892

Koray Harmanci

Department of Allergy, Ministry of Health, Ankara Diskapi Children’s Diseases Training and Research Hospital, Ankara, Turkey

Abstract: The cysteinyl leukotrienes, LTC4, LTD4, and LTE4, play an integral role in the pathophysiology of asthma. Acting via the type 1 leukotriene (CysLT1) receptor, these proinflammatory mediators have numerous effects in the lungs, including decreased activity of respiratory cilia, increased mucus secretion, increased venopermeability, and promotion of eosinophil migration into airway mucosa. Blocking studies show that Cys-LTs are pivotal mediators in the pathophysiology of asthma. Cys-LTs are key components in the early and late allergic airway response and also contribute to bronchial obstruction after exercise and hyperventilation of cold, dry air in asthmatics. Effects of the cysteinyl leukotrienes are blocked by leukotriene receptor antagonists; these agents inhibit bronchoconstriction in normal subjects provoked with inhaled cysteinyl leukotrienes, as well as in patients with asthma undergoing allergen, exercise, cold air, or aspirin challenge. Montelukast is a potent and selective blocker of the CysLT1 receptor. For treatment of chronic asthma, montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6–14 years as a 5-mg chewable tablet, and to children aged 2–5 years as a 4-mg chewable tablet form. Given their efficacy, antiinflammatory activity, oral administration, and safety, leukotriene modifiers will play an important role in the treatment of asthmatic children.

Keywords: montelukast, asthma, children, efficacy

Download Article [PDF] 

Readers of this article also read:

The benefit of atrial septal defect closure in elderly patients*

Komar M, Przewlocki T, Olszowska M, Sobien B, Podolec P

Clinical Interventions in Aging 2014, 9:1101-1107

Published Date: 16 July 2014

Nanolipodendrosome-loaded glatiramer acetate and myogenic differentiation 1 as augmentation therapeutic strategy approaches in muscular dystrophy

Afzal E, Zakeri S, Keyhanvar P, Bagheri M, Mahjoubi P, Asadian M, Omoomi N, Dehqanian M, Ghalandarlaki N, Darvishmohammadi T, Farjadian F, Golvajoee MS, Afzal S, Ghaffari M, Cohan RA, Gravand A, Ardestani MS

International Journal of Nanomedicine 2013, 8:2943-2960

Published Date: 8 August 2013

New developments in the management of hepatitis C virus infection: focus on boceprevir

Berenguer M, López-Labrador FX

Biologics: Targets and Therapy 2012, 6:249-256

Published Date: 3 August 2012

Clinical use of topical thrombin as a surgical hemostat

Wesley K Lew, Fred A Weaver

Biologics: Targets and Therapy 2008, 2:593-599

Published Date: 5 December 2008

A review of nasal polyposis

Jonathan Ray Newton, Kim Wong Ah-See

Therapeutics and Clinical Risk Management 2008, 4:507-512

Published Date: 11 April 2008

Satraplatin in the treatment of hormone-refractory metastatic prostate cancer

Andrew J Armstrong, Daniel J George

Therapeutics and Clinical Risk Management 2007, 3:877-883

Published Date: 15 November 2007